Concepedia

Author

Scott Brun

Abbott Fund

Also Known As

S Brun, S. Brun, SCOTT BRUN, Scott Brun

23

Publications

1.7K

Citations

12

H-Index

21

Concepts

All Affiliations

Abbott FundMedical University of South CarolinaAbbott (United States)University Medical Center New Orleans
SB

About

Scott Brun is an author at Abbott Fund specializing in medicine, hiv, and drug resistance.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

336

2

Pharmacology

2

2

159

3

Epidemiology

1

1

20

4

Immunology

1

1

91

5

Antibiotics

1

1

10

Scott Brun

×

14

Publications

1.7K

Citations

12

H-Index

YearCitations

Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

Sharon Walmsley, Barry Bernstein, Martin King,

New England Journal of Medicine

2002

647

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results

Robert L. Murphy, Scott Brun, Charles B. Hicks,

AIDS

2001

238

Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine

Dale J. Kempf, Martin King, Barry Bernstein,

The Journal of Infectious Diseases

2004

221

Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients

Ann Hsu, Jeffrey D. Isaacson, Scott Brun,

Antimicrobial Agents and Chemotherapy

2002

149

Selection of Resistance in Protease Inhibitor-Experienced, Human Immunodeficiency Virus Type 1-Infected Subjects Failing Lopinavir- and Ritonavir-Based Therapy: Mutation Patterns and Baseline Correlates

Hongmei Mo, Martin King, Kathryn King,

Journal of Virology

2005

91

Determining the Relative Efficacy of Highly Active Antiretroviral Therapy

Michael J. Louie, Christine Hogan, Michele Di Mascio,

The Journal of Infectious Diseases

2003

89

Cost-Effectiveness of Lopinavir/Ritonavir Versus Nelfinavir As the First-Line Highly Active Antiretroviral Therapy Regimen for HIV Infection

Kit N. Simpson, Michelle P. Luo, Elinor C. Chumney,

HIV Clinical Trials

2004

66

A Study of Topical Nonsteroidal Anti-inflammatory Drops and No Pressure Patching in the Treatment of Corneal Abrasions

Peter K. Kaiser, Roberto Pineda, Bonnie An,

Ophthalmology

1997

66

Liver Injury and Changes in Hepatitis C Virus (HCV) RNA Load Associated with Protease Inhibitor-Based Antiretroviral Therapy for Treatment-Naive HCV-HIV-Coinfected Patients: Lopinavir-Ritonavir versus Nelfinavir

Kenneth E. Sherman, Norah J. Shire, Paul Cernohous,

Clinical Infectious Diseases

2005

32

OCULAR TOXICITY OF INTRAVITREAL CLARITHROMYCIN

Melih Ünal, Gholam A. Peyman, Chanping Liang,

Retina

1999

21

Page 1